Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Published:2020-05-01 Issue:5 Volume:6 Page:661
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Rizvi Naiyer A.¹,Cho Byoung Chul²,Reinmuth Niels³,Lee Ki Hyeong⁴,Luft Alexander⁵,Ahn Myung-Ju⁶,van den Heuvel Michel M.⁷,Cobo Manuel⁸,Vicente David⁹,Smolin Alexey¹⁰,Moiseyenko Vladimir¹¹,Antonia Scott J.¹²,Le Moulec Sylvestre¹³,Robinet Gilles¹⁴,Natale Ronald¹⁵,Schneider Jeffrey¹⁶,Shepherd Frances A.¹⁷,Geater Sarayut Lucien¹⁸,Garon Edward B.¹⁹,Kim Edward S.²⁰,Goldberg Sarah B.²¹,Nakagawa Kazuhiko²²,Raja Rajiv²³,Higgs Brandon W.²³,Boothman Anne-Marie²⁴,Zhao Luping²³,Scheuring Urban²⁴,Stockman Paul K.²⁴,Chand Vikram K.²³,Peters Solange²⁵,

Affiliation:

1. Division of Hematology/Oncology, Columbia University Medical Center, New York, New York

2. Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

3. Asklepios Lung Clinic, Munich-Gauting, Germany

4. Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea

5. Department of Oncology No. 1 (Thoracic Surgery), Leningrad Regional Clinical Hospital, St Petersburg, Russia

6. Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea

7. Nederlands Kanker Instituut–Antoni van Leeuwenhoekziekenhuis, Amsterdam, the Netherlands

8. Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain

9. Department of Medical Oncology, Hospital Universitario Virgen Macarena, Seville, Spain

10. Department of Radiology, Burdenko Main Military Clinical Hospital, Moscow, Russia

11. Oncological Clinical Research Center, St Petersburg, Russia

12. H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

13. Department of Medical Oncology, Institut Bergonié, Bordeaux, France

14. Service de Pneumologie, Centre Hospitalier Régional Universitaire de Brest–Hôpital Morvan, Brest, France

15. Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California

16. Department of Hematology and Oncology, NYU Winthrop Hospital, Mineola, New York

17. Princess Margaret Cancer Centre and the Department of Medicine, University of Toronto, Toronto, Ontario, Canada

18. Department of Internal Medicine, Prince of Songkla University, Songkhla, Thailand

19. David Geffen School of Medicine, University of California/TRIO-US Network, Los Angeles

20. Levine Cancer Institute, Atrium Health, Charlotte, North Carolina

21. Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut

22. Faculty of Medicine, Department of Medical Oncology, Kindai University, Osaka, Japan

23. AstraZeneca, Gaithersburg, Maryland

24. AstraZeneca, Cambridge, United Kingdom

25. Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2763864/jamaoncology_rizvi_2020_oi_200006_1598029877.50744.pdf

Reference44 articles.

1. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.;Mok;Lancet,2019

2. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.;Gandhi;N Engl J Med,2018

3. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.;Socinski;N Engl J Med,2018

4. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.;West;Lancet Oncol,2019

5. IMpower132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC;Papadimitrakopoulou;J Thorac Oncol,2018

Cited by 481 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study;Cancer Immunology, Immunotherapy;2024-09-09

2. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

3. The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases;CLIN LUNG CANCER;2024

4. Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy;iScience;2024-09

5. The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases;Clinical Lung Cancer;2024-09